PAVmed exchanges $22.35M of convertible notes for Series C preferred; targets Nasdaq compliance

PAVmed Inc.

Exchanged $22,347,543 in principal plus interest of Senior Secured Convertible Notes for 22,347 Series C Preferred shares.
Remaining outstanding principal on Convertible Notes is approximately $6.6 million.
Potential dilution: at voluntary conversion price $1.068/share, ~20.9M common shares; at floor $0.2136, ~104.6M shares.
Company executed exchange to bolster stockholders' equity to meet Nasdaq minimum of $2.5M; compliance deadline Jan 31, 2025.

item 3.01 item 3.02 item 3.03 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.